SiteOne Therapeutics, Inc. raised $100 million in a Series C financing led by Novo Holdings to advance selective ion channel modulators for non-opioid treatments of pain.
SiteOne Therapeutics, Inc. raised $100 million in a Series C financing led by Novo Holdings to advance selective ion channel modulators for non-opioid treatments of pain.
12/18/24, 12:04 PM
Location
san franciscoMoney raised
$100 million
Industry
biotechnology
healthcare
Round Type
series c
Investors
Bsquared Capital, Mission Bio Capital, Wellington Management, Orbi Med, Novo Holdings
SiteOne Therapeutics, Inc. announced a $100 million Series C financing led by Novo Holdings with participation from several investors. The financing will support the development of their portfolio focused on treating sensory hyperexcitability disorders. SiteOne is dedicated to creating non-opioid treatments, and this funding will enable human clinical proof of concept studies.
Company Info
Location
280 utah ave., suite 250
san francisco, california, united states
Additional Info
SiteOne Therapeutics, Inc. is a biopharmaceutical company developing selective ion channel modulators aimed at treating conditions such as pain and cough. The company's focus is on creating non-opioid treatments that target sensory hyperexcitability disorders. Their lead program targets the NaV1.8 channel, with a focus on providing effective analgesia while minimizing side effects and abuse potential. SiteOne's innovative approach prioritizes the development of therapeutics that directly affect the peripheral nervous system.